Hansoh Pharma (03692) saw its share price advance nearly 4% in Thursday's trading session, last up 3.73% at HK$33.94, with turnover reaching HK$205 million. The rally comes amid fresh clinical data released at a major oncology conference.

According to reports, on September 13, the company presented interim results from the Phase III ARTEMIS-008 study of its self-developed B7-H3 targeting ADC therapy, Ris-Rez (HS-20093), at the 2026 World Conference on Lung Cancer's opening chairman forum. The presentation was made in the form of a breaking abstract. The disclosed data demonstrates that Ris-Rez has set a new record for the longest median overall survival in second-line treatment of small cell lung cancer (SCLC). Specifically, the median overall survival for Ris-Rez reached 18.5 months, compared to 10.3 months for the comparator topotecan.

Analysts are taking a bullish stance on the drug's potential. Jefferies expressed confidence in the potential best-in-class profile of Ris-Rez, suggesting the drug could expand into earlier lines of treatment. Meanwhile, J.P. Morgan maintained an "overweight" rating on Hansoh Pharma with a target price of HK$50, forecasting that the company's innovative drug sales and licensing revenues will drive a compound annual growth rate of 12% for revenue and 15% for profits from 2020 to 2030. The broker highlighted potential catalysts such as commercial drug sales, key data readouts from late-stage assets, and additional out-licensing deals.